Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  +5.50p +2.67% 211.50p 18,760,555 11:32:36
Bid Price Offer Price High Price Low Price Open Price
202.60p 203.40p 210.00p 201.10p 205.60p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 809.24 101.43 5.92 33.9 1,540.4

Indivior (INDV) Latest News (1)

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
03/10/201814:06RB. de-merger 488
31/7/201812:45Indivior (INDV) IP Battle Status -
28/7/201813:16Indivior (INDV) One to Watch on Monday 2
14/5/201812:52Indivior (INDV) Settles Legal Patent Battle -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-11-17 11:32:41211.50241,924511,669.26AT
2018-11-17 11:32:41211.50642,1171,358,077.46AT
2018-11-17 11:32:36211.5018,59039,317.85AT
2018-11-17 11:32:36211.50660,7071,397,395.31AT
2018-11-17 11:32:36211.50204,744433,033.56AT
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

Indivior Daily Update: Indivior is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 206p.
Indivior has a 4 week average price of 175.55p and a 12 week average price of 169.30p.
The 1 year high share price is 504.60p while the 1 year low share price is currently 169.30p.
There are currently 728,306,837 shares in issue and the average daily traded volume is 2,542,674 shares. The market capitalisation of Indivior is £1,540,368,960.26.
pwhite73: The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again.
naed: Very quite here......share price constantly loosing value?
steeplejack: Good recovery today,hope this presages a favourable court review. Plus... Indivior got a boost as Bank of America Merrill Lynch upgraded the stock to 'buy' following recent share price weakness.
kazoom: I am new to Indivior so apologies if this doesn't make sense - please feel free to correct me ;-) When I read "So Dr Reddy is really interested in testing punitive damages! I do wonder." I wonder if Dr Reddy are actually engaged in some Trump style bargaining. I note here Https:// (14-may) that INDV settled with PAR phara and that Par get the ability to sell the generic from Jan 2023 Maybe Reddy are angling for a similar settlement? Also if Par don't have the rights until 2023 - why would we expect the courts to grant a later comer like Reddy earlier access to the market? On that basis (and of course it could be nonsense) it seems to be that the outcome is likely to be much better than Friday's share price movement would suggest. Any thoughts?
gregmorg: Yup, as you say, who knows with this one! Good thing is it is increasingly looking a less dangerous/more secure company. So after the 2nd November we then roll on to that other tester of our investors steel --on the 14th. Will see how that coding scenario has developed . It could be the stock starts to put the days of serious uncertainty behind it. Revenues are looking good and growing very respectably. But what about the veins!~! Thinking of patience(or apathy!) I have been a little puzzled by GSK's share price performance in recent time but am hoping this baptism of fire gears up/fires up the new CEO. OR what! As for my other pharma, IMB, I do wish, Steeplejack, I had more noted your disposal some months back and so questioned my own rationale. Good call. Now I am left waiting for Vaping to kick in! Hopefully this is made less painless by a continued good stream of dividends. Let's see what tomorrow brings on IND . Unfortunately I cannot listen in to the live investors meeting as I have some silly cross country trail commitment. Hopefully I can listen in later in the day.
gregmorg: Steeplejack. I understand the Committee vote at the end was 18 for and one against.The latter was on the basis of this was nothing new! This, I hasten to add, is purely my understanding. I did say this Committee is advisory but it does look as if the recommendation to the FDA is going our way. A few concerns were raised re the results of the 300mg doses( as opposed to the 100mg) and a few small issues that resulted, but this does not appear to have affected the outcome. So possibly it is looking OK!. We both have experiences of erratic share price performance across the financial reporting period so its important to maintain the longer view.
gregmorg: Makes sense. Mind you, in terms of share price movement.The usual consensus is that a third give back after a significant share price rise is healthy! Steeplejack you mentio Merrills change of investment stance but purely for my edification can you say what their public stance was beforehand please? i was very happy to see that last piece of patent news so feel the longer term investment view remains intact.Essentially am sitting tight and awaiting events.
gregmorg: The share sales position has been very confusing with the legacy JAB disposal technically taking place between 9th Nov and 30 Nov. so no announcement in that period! My understanding is the institution which took the stake covered it with a series of complex hedging arrangements presumably allowing them to place their stock/or much of it, in the market with the minimum of fuss/publicity. The JAB disposal took time to soak up possibly weakening the share price over a period .Even 9th November could be a false start date as positions would have been taken well before then. So we could have some explanation for the share price performance since the summer! Actually I am less concerned with the recent term share price performance but more concerned with the longer term development of the product and revenue base. The Co's research and teach in date of 9 Dec is hopefully a significant event rather than one buying time. Not long to wait.
Indivior share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20181118 06:48:16